Home › Companies › BIONANO GENOMICS INC. › 2023-2024
At BIONANO GENOMICS INC.'s shareholder meeting held June 18, 2024, in the 2023-2024 proxy season, 64 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 164 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — BIONANO GENOMICS INC.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIONANO GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 21, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BIONANO GENOMICS INC.’s Form 8-K, filed June 21, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 18, 2024: 5 items on BIONANO GENOMICS INC.’s Form 8-K, filed June 21, 2024: 3 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore BIONANO GENOMICS INC. in the interactive database Compare manager voting policies
These tallies are BIONANO GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 21, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Christopher Twomey | 10,442,715 | -- | -- | 1,480,283 | 18,124,686 | 88% | Elected | — |
| Elect Director: Yvonne Linney, Ph.D. | 10,682,829 | -- | -- | 1,240,169 | 18,124,686 | 90% | Elected | — |
| Elect Director: Aleksander Rajkovic, M.D., Ph.D. | 10,810,303 | -- | -- | 1,112,695 | 18,124,686 | 91% | Elected | — |
| 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 9,508,999 | 1,771,611 | 642,388 | -- | 18,124,686 | 84% | Approved | — |
| 3. Ratification of the Selection of Independent Registered Public Accounting Firm | 26,950,772 | 2,788,563 | 308,349 | -- | -- | 91% | Approved | — |
Source: BIONANO GENOMICS INC., Form 8-K, filed with the SEC on June 21, 2024 — read the filing on EDGAR.
Each item below shows how the 64 asset managers that disclosed a BIONANO GENOMICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Aleksandar Rajkovic, M.D., Ph.D.
BIONANO GENOMICS INC.’s own tally for this item (“Elect Director: Aleksander Rajkovic, M.D., Ph.D.”): 10,810,303 for, 1,112,695 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 769,359 for, 4,688 withheld, 535 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 721,338 | 0 | 0 | 0 | For |
| Fidelity | 41,130 | 0 | 0 | 0 | For |
| Charles Schwab | 5,800 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 4,688 | Withhold |
| American Century | 861 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 535 | 0 | Abstain |
| CITY NATIONAL ROCHDALE FUNDS | 230 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Christopher Twomey
BIONANO GENOMICS INC.’s own tally for this item (“Elect Director: Christopher Twomey”): 10,442,715 for, 1,480,283 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 769,359 for, 4,688 withheld, 535 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 721,338 | 0 | 0 | 0 | For |
| Fidelity | 41,130 | 0 | 0 | 0 | For |
| Charles Schwab | 5,800 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 4,688 | Withhold |
| American Century | 861 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 535 | 0 | Abstain |
| CITY NATIONAL ROCHDALE FUNDS | 230 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Yvonne Linney, Ph.D.
BIONANO GENOMICS INC.’s own tally for this item (“Elect Director: Yvonne Linney, Ph.D.”): 10,682,829 for, 1,240,169 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 768,498 for, 5,549 withheld, 535 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 721,338 | 0 | 0 | 0 | For |
| Fidelity | 41,130 | 0 | 0 | 0 | For |
| Charles Schwab | 5,800 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 4,688 | Withhold |
| American Century | 0 | 0 | 0 | 861 | Withhold |
| Jackson National | 0 | 0 | 535 | 0 | Abstain |
| CITY NATIONAL ROCHDALE FUNDS | 230 | 0 | 0 | 0 | For |
Combines 9 wordings of this item as funds reported it.
84% Approved · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.
BIONANO GENOMICS INC.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 9,508,999 for, 1,771,611 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the Annual Meeting.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 721,338 | 0 | 0 | 0 | For |
| Fidelity | 41,130 | 0 | 0 | 0 | For |
| Charles Schwab | 5,800 | 0 | 0 | 0 | For |
| Dimensional | 0 | 4,688 | 0 | 0 | Against |
| American Century | 861 | 0 | 0 | 0 | For |
| Jackson National | 0 | 535 | 0 | 0 | Against |
| CITY NATIONAL ROCHDALE FUNDS | 230 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 769,359 for, 5,223 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 4,860,000 | 0 | 0 | 0 | For |
| GMT CAPITAL CORP | 139,406 | 0 | 0 | 0 | For |
| BlackRock | 123,935 | 0 | 0 | 0 | For |
| T. Rowe Price | 70,370 | 0 | 0 | 0 | For |
| Northern Trust | 58,337 | 0 | 0 | 0 | For |
| Citadel | 44,697 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 41,940 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 34,353 | 0 | 0 | 0 | For |
| Atom Investors LP | 25,596 | 0 | 0 | 0 | For |
| State Street | 23,396 | 0 | 0 | 0 | For |
| Two Sigma | 17,000 | 0 | 0 | 0 | For |
| Fidelity | 16,284 | 0 | 0 | 0 | For |
| Vanguard | 10,393 | 0 | 0 | 0 | For |
| Point72 | 10,141 | 0 | 0 | 0 | For |
| Charles Schwab | 5,800 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 3,749 | 0 | 0 | 0 | For |
| BANK OF MONTREAL /CAN/ | 3,203 | 0 | 0 | 0 | For |
| Goldman Sachs | 2,231 | 0 | 0 | 0 | For |
| OPPENHEIMER & CO INC | 1,584 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,371 | 0 | 0 | Against |
| Fisher Asset Management, LLC | 969 | 0 | 0 | 0 | For |
| American Century | 861 | 0 | 0 | 0 | For |
| Belpointe Asset Management LLC | 638 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 600 | 0 | 0 | 0 | For |
| TD ASSET MANAGEMENT INC | 517 | 0 | 0 | 0 | For |
Institutional-manager reports, all 60 managers: 5,499,966 for, 1,579 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
91% Approved · of votes cast
Description as filed by funds: To ratify the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
BIONANO GENOMICS INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 26,950,772 for, 2,788,563 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 774,582 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 721,338 | 0 | 0 | 0 | For |
| Fidelity | 41,130 | 0 | 0 | 0 | For |
| Charles Schwab | 5,800 | 0 | 0 | 0 | For |
| Dimensional | 4,688 | 0 | 0 | 0 | For |
| American Century | 861 | 0 | 0 | 0 | For |
| Jackson National | 535 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 230 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 66,856,804 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.08% |
| 2 | Fidelity | 0.06% |
| 3 | Charles Schwab | <0.01% |
| 4 | Dimensional | <0.01% |
| 5 | American Century | <0.01% |
| 6 | Jackson National | <0.01% |
| 7 | CITY NATIONAL ROCHDALE FUNDS | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 7.27% |
| 2 | GMT CAPITAL CORP | 0.21% |
| 3 | BlackRock | 0.19% |
| 4 | T. Rowe Price | 0.11% |
| 5 | Northern Trust | 0.09% |
| 6 | Citadel | 0.07% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.06% |
| 8 | STIFEL NICOLAUS & CO INC \MO\ | 0.05% |
| 9 | Atom Investors LP | 0.04% |
| 10 | State Street | 0.03% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| The Vanguard Group | 2.83% | 13G |
| Geode Capital | 0.60% | 13F |
| Citadel Advisors | 0.58% | 13F |
| CVI Investments, Inc. | 0.24% | 13G |
| State Street | 0.17% | 13F |
| Northern Trust | 0.16% | 13F |
| Aleksandar Rajkovik, M.D., Ph.D. | 0.12% | DEF14A |
| Yvonne Linney, Ph.D. | 0.11% | DEF14A |
| Albert Luderer, Ph.D. | 0.11% | DEF14A |
| Kristiina Vuori, M.D., Ph.D. | 0.11% | DEF14A |
Percentages above are of 66,856,804 shares outstanding, as reported by BIONANO GENOMICS INC. on its Form 10-Q dated May 6, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIONANO GENOMICS INC.’s 10-Q dated May 6, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
BIONANO GENOMICS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “BIONANO GENOMICS (BNGO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/bionano-genomics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.